Compare Amgen, Inc. (AMGN) vs Exxon Mobil Corporation (XOM) Price & Performance

Amgen, Inc.Trade

Exxon Mobil CorporationTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Exxon Mobil Corporation — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Exxon Mobil Corporation trades at $144.74 (market cap $575.65B). The key difference: Exxon Mobil Corporation is far larger — about 2.9× Amgen, Inc.'s market cap, and Exxon Mobil Corporation pays the higher dividend (2.97%). Which is the better fit depends on your goals.

	AMGN	XOM
Market Cap	$196.12B	$575.65B
Sector	Health	Energy
52-Week High	$388.16	$171.52
52-Week Low	$271.18	$105.83
Enterprise Value	$241.41B	$614.88B
Dividend Yield	2.77%	2.97%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

No Aura AI signal available yet.

Exxon Mobil Corporation

ExxonMobil (XOM) trades at $138.83, up 1.06% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.16, beating estimates, while revenue declined to $323.91 billion in 2025. Analyst consensus is mixed with 42.59% buy ratings and a $169.30 price target. Recent news highlights Exxon's Permian Basin advantages and warnings of potential oil price spikes to $160 per barrel amid Middle East tensions.

XOM offers value with a P/E of 23.38 and strong cash flow, but faces headwinds from declining revenue and net income margins. Investment appeal hinges on oil price stability and execution in low-breakeven assets like the Permian Basin. Risks include volatile energy markets and geopolitical tensions affecting global supply.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

View details →

XOM

US oil majors see huge profits from Iran war but resist drilling more despite Trump pressureNew York Post · 3 days agoBullish Global wax market to reach $16.65B by 2035 driven by packaging, cosmetics, and industrial demand.Sns Insider · 3 days agoBullish Generative AI in oil and gas market to grow at 16.9% CAGR, reaching $1.15B by 2030 with cloud and predictive tech driving growth.Researchandmarkets.Com · 3 days agoBullish View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Exxon Mobil Corporation

Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.